Jose G. Montoya MD
Mycoplasma and Ureaplasma species (mycoplasmas) are ubiquitous in nature and are commonly found in plants, animals, and humans. These bacteria contain the smallest amount of double-stranded DNA that is capable of producing a free-living microorganism; they measure between 0.15 and 0.3 µm in diameter and ≤ 2 µm in length. They are believed to have evolved from a putative common ancestor of the gram-positive bacteria by a process of genome reduction and adoption of a dependent, parasitic life style. Mycoplasma and Ureaplasma spp. lack a cell wall. Therefore, they cannot be visualized with the Gram stain and are not susceptible to antibiotics that act on cell wall synthesis (eg, penicillins and cephalosporins). They are capable of growing in cell-free media, but require many exogenous nutrients for growth, including sterols. In addition to Ureaplasma urealyticum, 13 species of Mycoplasma have been isolated from humans; however, most of them are not regarded as pathogens.
Mycoplasmas are the etiologic agents and cofactors of several clinical syndromes in humans. Mycoplasma pneumoniae is a common cause of community-acquired pneumonia. U urealyticum and Mycoplasma genitalium most often cause genitourinary tract infections; U urealyticum has also been associated with perinatal morbidity and mortality, as well as with disease outside the genitourinary tract, especially in children. Mycoplasma hominis is an infrequent cause of bone, joint, and upper urinary tract disease.
M PNEUMONIAE INFECTION & DISEASE
M pneumoniae is an important cause of upper and lower respiratory infections in both adults and children. Extrapulmonary involvement, including dermatological, neurological, cardiac, musculoskeletal, and vasculitic involvement, has also been associated with M pneumoniae infection in humans.
Essentials of Diagnosis
Clinical Findings (Box 66-1)
Patients develop respiratory symptoms 2–3 weeks after exposure to the respiratory secretions of another infected individual. M pneumoniaerespiratory tract disease usually presents with gradual onset of fever, malaise, headache, and cough. The cough is usually minimally productive or nonproductive and is “hacking” in most patients; it can become debilitating or incapacitating and may produce sternal discomfort. Most of these symptoms resolve spontaneously in the vast majority of patients. However, in a minority, these upper respiratory symptoms progress to tracheobronchitis or pneumonia. On occasion, M pneumoniae pneumonia begins abruptly. Pleuritic chest pain is rare and must be distinguished from the chest soreness due to muscle strain in cases of severe cough. Body temperature usually fluctuates between 101 and 102°F; however, occasional temperature spikes > 102°F can be seen. On physical examination, most patients do not appear acutely ill. The pharynx may appear erythematous, but cervical lymphadenopathy is rare or absent. M pneumoniae is a rare cause of isolated pharyngitis in children and adults. Lung auscultation may be entirely normal or may disclose only a few crackles.
BOX 66-1 Mycoplasma pneumoniae Disease
Methods for diagnosing M pneumoniae infection include cultivation, antigen and nucleic acid detection, and serology. Cultivation of M pneumoniae from tracheal aspirates, nasopharyngeal swabbings, sputum, or any body fluid should be attempted if the methods are available but they have a low yield and are cumbersome to perform due to the complex growth requirements of the organism. Specimens for culture should be transported in special media.
Detection of M pneumoniae antigens directly in sputum specimens is feasible by using a direct fluorescent antibody method or antigen-capture enzyme immunoassay, but the role of these antigens in the diagnosis of M pneumoniae disease has not been well established. Methods for detecting M pneumoniae DNA are also commercially available for use with throat swabs but are not available in most laboratories.
Serological testing is the most widely available and widely used approach for diagnosing M pneumoniae infections. Serological tests are rarely helpful during the acute illness. Paired measurements are most helpful; a fourfold titer difference between the acute and the convalescent serum antibody titer is considered diagnostic. Single measurements are of value for epidemiological purposes. IgG- and IgM-specific antibodies can be detected with indirect immunofluorescent antibody or enzyme immunoassay methods. Because of ease of use and reliability, enzyme immunoassay has become the preferred method. A complement fixation assay is less sensitive and is reserved for epidemiological purposes.
Demonstration of cold agglutinins can help to support the diagnosis of M pneumoniae pneumonia, although the finding is nonspecific. Cold agglutinins have been observed in adenovirus infections, infectious mononucleosis, cytomegalovirus infection, lymphoma, and other diseases. Nonetheless, a titer of ≥ 1:32 is highly suggestive of infection with M pneumoniae. Cold agglutinins can also be detected at the bedside by drawing 1 mL of the patient's blood into a blue top tube (containing citrate as the anticoagulant) and cooling the tube at 4°C for 3–4 min. The reversible appearance of macroagglutination indicates the presence of cold agglutinins at a titer of approximately ≥ 1:64.
Legionella spp., Chlamydia pneumoniae, Chlamydia psittaci, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis can cause a pneumonia with clinical features that are indistinguishable from those associated with M pneumoniae.
The efficacy of antimicrobial agents in patients with M pneumoniae pneumonia is difficult to evaluate because this is often a self-limited disease. Antibiotics most likely shorten the duration of symptoms and may have an important role when infected patients are immunocompromised or are severely affected by the disease.
The most effective antimicrobial agents are macrolides, fluoroquinolones, and tetracyclines (Box 66-2). Macrolides are the first-line agents for treatment of M pneumoniae-associated disease. Azithromycin and clarithromycin are better tolerated and easier to administer than erythromycin, but are more expensive. Fluoroquinolones should not be used in patients younger than 18 years, and tetracyclines should not be used in children younger than 9. The newer fluoroquinolones (levofloxacin, moxifloxacin, and gatifloxacin) with enhanced activity against S pneumoniae have reliable activity in vitro against M pneumoniae. Most patients with pneumonia do not require hospitalization and are treated on an empirical basis. The recommended duration of therapy is not clear. Clinical relapse occurs in ~ 10% of patients and may warrant a longer course of antibiotic therapy, eg, 3 weeks.
Radiological improvement may lag behind clinical improvement for weeks.
There are currently no recommended specific control measures for M pneumoniae outbreaks in closed communities. However, some studies have suggested the usefulness of prophylactic antibiotics administered to close contacts of case patients. One study demonstrated that the administration of azithromycin, 500 mg on day 1 and 250 mg on days 2–5, to individuals at risk was beneficial in reducing the disease attack rate during an institutional outbreak of M pneumoniae pneumonia. There is no available vaccine.
BOX 66-2 Treatment of Mycoplasma pneumoniae Infections1
INFECTIONS CAUSED BY U UREALYTICUM & OTHER MYCOPLASMAS
U urealyticum, M hominis, and M genitalium are commensals of the genitourinary tract of both women and men and in newborns. U urealyticum is an infrequent cause of urethritis in males, urinary calculi, chorioamnionitis, spontaneous abortion, and premature birth. M genitalium is also associated with male urethritis. M hominis is a rare cause of pyelonephritis, pelvic inflammatory disease, and postabortal and postpartum fevers.
U urealyticum and M hominis can cause disease outside the genitourinary tract in immunosuppressed patients or in otherwise immunocompetent patients after manipulation or trauma of the genitourinary tract. M hominis can cause sternal wound infections and osteomyelitis, arthritis (especially in hypogammaglobulinemic patients), brain abscess, pneumonia, and peritonitis. It has been associated with neonatal pneumonia and sepsis. In immunosuppressed patients, U urealyticum can cause arthritis, osteomyelitis, sinusitis, and pneumonia. It can also cause neonatal pneumonia and sepsis.
A thorough search for other causes should be completed before U urealyticum or M hominis can be considered the etiologic agent of any of the above syndromes.
Mycoplasma penetrans, Mycoplasma pirum, and Mycoplasma fermentans have been associated with HIV infection and with the progression to AIDS; however, there is little evidence for a causal role of these organisms in this disease process. The associations more likely reflect the enhanced susceptibility of the HIV-infected host to secondary mycoplasma infection.
M hominis can be treated with tetracyclines or with clindamycin. U urealyticum infections can be treated with tetracyclines, erythromycin, or azithromycin. Both U urealyticum and M hominis can be resistant to the tetracyclines. M hominis is resistant to the macrolides.
Fenollar F et al: Mycoplasma infections of aneurysms or vascular grafts. Clin Infect Dis 1999;28:694.
Hutchison CA et al: Global transposon mutagenesis and a minimal Mycoplasma genome. Science 1999;286:2165.
Klausner JD et al: Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis. J Infect Dis 1998;177:161.
Razin S, Yogev D, Naot Y: Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 1998; 62:1094.
Rottem S, Naot Y: Subversion and exploitation of host cells by mycoplasmas. Trends Microbiol 1998;6:436.